Fasching PA - Search Results

1

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.

Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, Anglesio MS, Ataseven B, Barlow E, Beckmann MW, Berger J, Bisinotto C, Bösmüller H, Boros J, Brand AH, Brooks-Wilson A, Brucker SY, Carney ME, Casablanca Y, Cazorla-Jiménez A, Cohen PA, Conrads TP, Cook LS, Coulson P, Courtney-Brooks M, Cramer DW, Crowe P, Cunningham JM, Cybulski C, Darcy KM, El-Bahrawy MA, Elishaev E, Erber R, Farrell R, Fereday S, Fischer A, García MJ, Gayther SA, Gentry-Maharaj A, Gilks CB; AOCS Group; Grube M, Harnett PR, Harrington SP, Harter P, Hartmann A, Hecht JL, Heikaus S, Hein A, Heitz F, Hendley J, Hernandez BY, Polo SH, Heublein S, Hirasawa A, Høgdall E, Høgdall CK, Horlings HM, Huntsman DG, Huzarski T, Jewell A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Khabele D, Kommoss FKF, Kruitwagen RFPM, Lambrechts D, Le ND, Lener M, Lester J, Leung Y, Linder A, Loverix L, Lubiński J, Madan R, Maxwell GL, Modugno F, Neuhausen SL, Olawaiye A, Olbrecht S, Orsulic S, Palacios J, Pearce CL, Pike MC, Quinn CM, Mohan GR, Rodríguez-Antona C, Ruebner M, Ryan A, Salfinger SG, Sasamoto N, Schildkraut JM, Sch… See abstract for full author list ➔ Kang EY, et al. Among authors: fasching pa. Cancer. 2023 Mar 1;129(5):697-713. doi: 10.1002/cncr.34582. Epub 2022 Dec 26. Cancer. 2023. PMID: 36572991 Free PMC article.

2

Hereditary breast and ovarian cancer: review and future perspectives.

Lux MP, Fasching PA, Beckmann MW. Lux MP, et al. Among authors: fasching pa. J Mol Med (Berl). 2006 Jan;84(1):16-28. doi: 10.1007/s00109-005-0696-7. Epub 2005 Nov 11. J Mol Med (Berl). 2006. PMID: 16283147 Review.

3

Age of uptake of early cancer detection facilities by low-risk and high-risk patients with familial breast and ovarian cancer.

Lux MP, Ackermann S, Bani MR, Nestle-Krämling C, Goecke TO, Niederacher D, Bodden-Heidrich R, Bender HG, Beckmann MW, Fasching PA. Lux MP, et al. Among authors: fasching pa. Eur J Cancer Prev. 2005 Dec;14(6):503-11. doi: 10.1097/00008469-200512000-00003. Eur J Cancer Prev. 2005. PMID: 16284494

4

Influence of mammographic density on the diagnostic accuracy of tumor size assessment and association with breast cancer tumor characteristics.

Fasching PA, Heusinger K, Loehberg CR, Wenkel E, Lux MP, Schrauder M, Koscheck T, Bautz W, Schulz-Wendtland R, Beckmann MW, Bani MR. Fasching PA, et al. Eur J Radiol. 2006 Dec;60(3):398-404. doi: 10.1016/j.ejrad.2006.08.002. Epub 2006 Oct 9. Eur J Radiol. 2006. PMID: 17030108

5

The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs.

Fasching PA, von Minckwitz G, Fischer T, Kaufmann M, Schultz-Zehden B, Beck H, Lux MP, Jacobs V, Meden H, Kiechle M, Beckmann MW, Paepke S. Fasching PA, et al. Breast Cancer Res Treat. 2007 Jan;101(1):95-104. doi: 10.1007/s10549-006-9272-2. Epub 2006 Oct 11. Breast Cancer Res Treat. 2007. PMID: 17033928

6

Acceptance for preventive genetic testing and prophylactic surgery in women with a family history of breast and gynaecological cancers.

Ackermann S, Lux MP, Fasching PA, Strissl P, Renner SP, Poehls U, Bender HG, Beckmann MW. Ackermann S, et al. Among authors: fasching pa. Eur J Cancer Prev. 2006 Dec;15(6):474-9. doi: 10.1097/01.cej.0000220628.62610.ea. Eur J Cancer Prev. 2006. PMID: 17106324

7

Hormones and genetics caught in the crossfire of preventive medicine.

Fasching PA, Beckmann MW. Fasching PA, et al. Lancet Oncol. 2007 Jan;8(1):5-6. doi: 10.1016/S1470-2045(06)70987-1. Lancet Oncol. 2007. PMID: 17196506 No abstract available.

8

Evaluation of mathematical models for breast cancer risk assessment in routine clinical use.

Fasching PA, Bani MR, Nestle-Krämling C, Goecke TO, Niederacher D, Beckmann MW, Lux MP. Fasching PA, et al. Eur J Cancer Prev. 2007 Jun;16(3):216-24. doi: 10.1097/CEJ.0b013e32801023b3. Eur J Cancer Prev. 2007. PMID: 17415092

9

Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.

Fasching PA, Loehberg CR, Strissel PL, Lux MP, Bani MR, Schrauder M, Geiler S, Ringleff K, Oeser S, Weihbrecht S, Schulz-Wendtland R, Hartmann A, Beckmann MW, Strick R. Fasching PA, et al. Breast Cancer Res Treat. 2008 Nov;112(1):89-98. doi: 10.1007/s10549-007-9822-2. Epub 2007 Nov 30. Breast Cancer Res Treat. 2008. PMID: 18049890

10

Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer.

Schrauder M, Frank S, Strissel PL, Lux MP, Bani MR, Rauh C, Sieber CC, Heusinger K, Hartmann A, Schulz-Wendtland R, Strick R, Beckmann MW, Fasching PA. Schrauder M, et al. Among authors: fasching pa. J Cancer Res Clin Oncol. 2008 Aug;134(8):873-82. doi: 10.1007/s00432-008-0355-9. Epub 2008 Feb 9. J Cancer Res Clin Oncol. 2008. PMID: 18264724

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

809 results

Search Page